000142612 001__ 142612
000142612 005__ 20240229105149.0
000142612 0247_ $$2doi$$a10.1093/neuonc/noy111
000142612 0247_ $$2pmid$$apmid:30010851
000142612 0247_ $$2pmc$$apmc:PMC6231209
000142612 0247_ $$2ISSN$$a1522-8517
000142612 0247_ $$2ISSN$$a1523-5866
000142612 0247_ $$2altmetric$$aaltmetric:44963416
000142612 037__ $$aDKFZ-2019-00330
000142612 041__ $$aeng
000142612 082__ $$a610
000142612 1001_ $$aNowak, Johannes$$b0
000142612 245__ $$aMagnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor.
000142612 260__ $$aOxford$$bOxford Univ. Press$$c2018
000142612 3367_ $$2DRIVER$$aarticle
000142612 3367_ $$2DataCite$$aOutput Types/Journal article
000142612 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550756538_27365
000142612 3367_ $$2BibTeX$$aARTICLE
000142612 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142612 3367_ $$00$$2EndNote$$aJournal Article
000142612 520__ $$aRecently, 3 molecular subgroups of atypical teratoid/rhabdoid tumor (ATRT) were identified, but little is known of their clinical and magnetic resonance imaging (MRI) characteristics.A total of 43 patients with known molecular subgroup status (ATRT-sonic hedgehog [SHH], n = 17; ATRT-tyrosine [TYR], n = 16; ATRT-myelocytomatosis oncogene [MYC], n = 10) were retrieved from the EU-RHAB Registry and analyzed for clinical and MRI features.On MRI review, differences in preferential tumor location were confirmed, with ATRT-TYR being predominantly located infratentorially (P < 0.05). Peritumoral edema was more pronounced in ATRT-MYC compared with ATRT-SHH (P < 0.05) and ATRT-TYR (P < 0.05). Conversely, peripheral tumor cysts were found more frequently in ATRT-SHH (71%) and ATRT-TYR (94%) compared with ATRT-MYC (40%, P < 0.05). Contrast enhancement was absent in 29% of ATRT-SHH (0% of ATRT-TYR; 10% of ATRT-MYC; P < 0.05), and there was a trend toward strong contrast enhancement in ATRT-TYR and ATRT-MYC. We found the characteristic (bandlike) enhancement in 28% of ATRT as well as restricted diffusion in the majority of tumors. A midline/off-midline location in the posterior fossa was also not subgroup specific. Visible meningeal spread (M2) at diagnosis was rare throughout all subgroups.These exploratory findings suggest that MRI features vary across the 3 molecular subgroups of ATRT. Within future prospective trials, MRI may aid diagnosis and treatment stratification.
000142612 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000142612 588__ $$aDataset connected to CrossRef, PubMed,
000142612 7001_ $$aNemes, Karolina$$b1
000142612 7001_ $$aHohm, Annika$$b2
000142612 7001_ $$aVandergrift, Lindsey A$$b3
000142612 7001_ $$aHasselblatt, Martin$$b4
000142612 7001_ $$0P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aJohann, Pascal$$b5$$udkfz
000142612 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b6$$udkfz
000142612 7001_ $$aFrühwald, Michael C$$b7
000142612 7001_ $$aWarmuth-Metz, Monika$$b8
000142612 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy111$$gVol. 20, no. 12, p. 1672 - 1679$$n12$$p1672 - 1679$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000142612 909CO $$ooai:inrepo02.dkfz.de:142612$$pVDB
000142612 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142612 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000142612 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142612 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142612 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142612 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142612 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142612 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142612 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142612 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142612 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000142612 9141_ $$y2018
000142612 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142612 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142612 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000142612 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000142612 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000142612 980__ $$ajournal
000142612 980__ $$aVDB
000142612 980__ $$aI:(DE-He78)B062-20160331
000142612 980__ $$aI:(DE-He78)L101-20160331
000142612 980__ $$aUNRESTRICTED